Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by ...

Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in certain ...

Arima Genomics announces a new study showing that the Aventa™ lymphoma test resolves diagnostic ambiguity and guides care in ...

Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by The Institute of Cancer ...

CHATSWORTH, Calif., Nov. 29, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized ...

A new analysis found patients with high-cytogenetic-risk multiple myeloma benefitted from adding daratumumab to their therapy. Daratumumab with bortezomib/dexamethasone (D-Vd) led to better ...

SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has acquired Lineagen Inc., a Salt Lake City, Utah based genetic diagnostic company, further ...

The "Genetic Testing Market by Type, Technology, Application: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com’s offering. The genetic ...

SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets the Saphyr® system, a genome imaging platform for ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ ...